JPMorgan: Optimistic about the prospects of Gilead Sciences's cancer business, upgraded the rating to "overweight"

8
Comment
Favorite

JPMorgan: Optimistic about the prospects of Gilead Sciences's cancer business, upgraded the rating to "overweight"

智通财经2022-10-04

On Tuesday, JPMorgan upgraded Gilead Sciences's rating to "overweight" from "neutral," citing greater clarity on the company's HIV business and having an emerging but undervalued oncology business. JPMorgan also raised its December 2023 target price for the stock to $80, citing Gilead's recent settlement with several generic drug makers over a patent for tenofovir alafenamide, an ingredient used to treat AIDS. In addition, the company also mentioned long-term development opportunities for lenacapavir. lenacapavir is an experimental...

Web link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Allen Chin
·2022-10-04
666
Reply
1
Report
Fold Replies
- Allen Chin:
  666
  2022-10-05
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2272855289?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/03ecb2bfde9f4064ad649d46a66296a8","is_english":false,"pubTime":"2022-10-04 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2272855289","market":"us","top_or_hot":-1,"title":"JPMorgan: Optimistic about the prospects of Gilead Sciences's cancer business, upgraded the rating to \"overweight\"","media":"智通财经","content":"<p><div>On Tuesday, JPMorgan upgraded Gilead Sciences's rating to \"overweight\" from \"neutral,\" citing greater clarity on the company's HIV business and having an emerging but undervalued oncology business. JPMorgan also raised its December 2023 target price for the stock to $80, citing Gilead's recent settlement with several generic drug makers over a patent for tenofovir alafenamide, an ingredient used to treat AIDS. In addition, the company also mentioned long-term development opportunities for lenacapavir. lenacapavir is an experimental...</p><p><a href=\"http://www.zhitongcaijing.com/content/detail/801543.html\">Web link</a></div></p>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan: Optimistic about the prospects of Gilead Sciences's cancer business, upgraded the rating to \"overweight\"</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan: Optimistic about the prospects of Gilead Sciences's cancer business, upgraded the rating to \"overweight\"\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2022-10-04 21:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>On Tuesday, JPMorgan upgraded Gilead Sciences's rating to \"overweight\" from \"neutral,\" citing greater clarity on the company's HIV business and having an emerging but undervalued oncology business. JPMorgan also raised its December 2023 target price for the stock to $80, citing Gilead's recent settlement with several generic drug makers over a patent for tenofovir alafenamide, an ingredient used to treat AIDS. In addition, the company also mentioned long-term development opportunities for lenacapavir. lenacapavir is an experimental...</p><p><a href=\"http://www.zhitongcaijing.com/content/detail/801543.html\">Web link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/801543.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/801543.html","article_id":"2272855289","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/03ecb2bfde9f4064ad649d46a66296a8"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2272855289","pubTimestamp":1664890866,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"周二，摩根大通将吉利德科学评级从“中性”上调至“增持”，理由是该公司艾滋病毒业务更加明朗，以及拥有一个新兴但被低估的肿瘤业务。小摩还将该股2023年12月的目标价格上调至80美元，原因是吉利德最近与几","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"Xiaomo: Optimistic about the prospects of Gilead Sciences's cancer business and upgrade the rating to \"overweight\"","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/c7e7c4470e0069e49d9a612822f96387","symbols_score_info":{"GILD":1},"content_text":"周二，摩根大通将吉利德科学评级从“中性”上调至“增持”，理由是该公司艾滋病毒业务更加明朗，以及拥有一个新兴但被低估的肿瘤业务。小摩还将该股2023年12月的目标价格上调至80美元，原因是吉利德最近与几家仿制药制造商就tenofovir alafenamide专利达成和解，该药物是一种用于治疗艾滋病的成分。此外，该公司还提到了lenacapavir的长期发展机会。lenacapavir是一种实验性艾滋病治疗药物，目前正在接受FDA的审查，其预定生效日期为12月27日。分析师写道:“在目前的水平上，我们认为仅吉利德科学的艾滋病业务就支撑了整个股票市值。”到2030年，吉利德的癌症业务组合预计将增加约50亿美元的销售额，分析师认为，该股票“在目前的水平上明显被低估了”，因为他们指出，lenacapavir的估值将进一步上涨，而HIV业务被低估。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[{"id":9912478170,"gmtCreate":1664892589690,"gmtModify":1676537524467,"author":{"id":"3559650667138314","authorId":"3559650667138314","name":"Allen Chin","avatar":"https://static.tigerbbs.com/60f340cd51eeb7333492dbf6f08dcd8a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9912478170","repostId":2272855289,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104224237,"gmtCreate":1664938200650,"gmtModify":1664938204015,"authorId":3559650667138314,"author":{"id":3559650667138314,"authorId":3559650667138314,"name":"Allen Chin","avatar":"https://static.tigerbbs.com/60f340cd51eeb7333492dbf6f08dcd8a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9912478170,"type":1,"supId":0,"prevId":0,"content":"666","text":"666","html":"666"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}